The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients

被引:0
|
作者
Doreen Z. Mhandire
Andrew K. L. Goey
机构
[1] Roswell Park Comprehensive Cancer Center,Department of Pharmacology and Therapeutics
来源
Molecular Diagnosis & Therapy | 2022年 / 26卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Many anticancer drugs cause adverse drug reactions (ADRs) that negatively impact safety and reduce quality of life. The typical narrow therapeutic range and exposure-response relationships described for anticancer drugs make precision dosing critical to ensure safe and effective drug exposure. Germline mutations in pharmacogenes contribute to inter-patient variability in pharmacokinetics and pharmacodynamics of anticancer drugs. Patients carrying reduced-activity or loss-of-function alleles are at increased risk for ADRs. Pretreatment genotyping offers a proactive approach to identify these high-risk patients, administer an individualized dose, and minimize the risk of ADRs. In the field of oncology, the most well-studied gene-drug pairs for which pharmacogenetic dosing recommendations have been published to improve safety are DPYD-fluoropyrimidines, TPMT/NUDT15-thiopurines, and UGT1A1-irinotecan. Despite the presence of these guidelines, the scientific evidence showing the benefits of pharmacogenetic testing (e.g., improved safety and cost-effectiveness) and the development of efficient multi-gene genotyping panels, routine pretreatment testing for these gene-drug pairs has not been implemented widely in the clinic. Important considerations required for widespread clinical implementation include pharmacogenetic education of physicians, availability or allocation of institutional resources to build an efficient clinical infrastructure, international standardization of guidelines, uniform adoption of guidelines by regulatory agencies leading to genotyping requirements in drug labels, and development of cohesive reimbursement policies for pretreatment genotyping. Without clinical implementation, the potential of pharmacogenetics to improve patient safety remains unfulfilled.
引用
收藏
页码:137 / 151
页数:14
相关论文
共 50 条
  • [1] The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients
    Mhandire, Doreen Z.
    Goey, Andrew K. L.
    MOLECULAR DIAGNOSIS & THERAPY, 2022, 26 (02) : 137 - 151
  • [2] A multifaceted intervention to reduce drug-related complications in surgical patients
    Bos, Jacqueline M.
    van den Bemt, Patricia M. L. A.
    Kievit, Wietske
    Pot, Johan L. W.
    Nagtegaal, J. Elsbeth
    Wieringa, Andre
    van der Westerlaken, Monique M. L.
    van der Wilt, Gert Jan
    de Smet, Peter A. G. M.
    Kramers, Cornelis
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (03) : 664 - 677
  • [3] Drug-Related Retinal Toxicity in SLE
    Mukwikwi, Elvis-Raymond
    Pineau, Christian
    Vinet, Evelyne
    Clarke, Ann
    Nashi, Emil
    Kalache, Fares
    Grenier, Louis-Pierre
    Bernatsky, Sasha
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (07) : 988 - 988
  • [4] Drug-related problems identified in hospitalized cancer patients
    Umar, Rashida Muhammad
    Yumuk, Perran Fulden
    Apikoglu-Rabus, Sule
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (01) : 246 - 246
  • [6] Drug-related problems in cancer patients: A systematic review
    Venugopal, Jayalakshmi
    Shalini, S.
    Rajasekaran, A.
    Karnan, Deepika
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (03) : 562 - 571
  • [7] Refractory cancer pain and drug-related toxicity controlled by an implantable drug delivery system
    Nature Clinical Practice Oncology, 2005, 2 (7): : 329 - 330
  • [8] Aberrant drug-related behaviors in patients with cancer and AIDS
    Tolbert, VE
    Passik, SD
    Kirsh, KL
    Wolf, J
    Donaghy, KB
    Anderson, R
    Portenoy, RK
    PSYCHO-ONCOLOGY, 2003, 12 (04) : S117 - S117
  • [9] Causality assessment of drug-related liver toxicity
    Schulze, J.
    Siegers, C. -P.
    TOXICOLOGY LETTERS, 2006, 164 : S145 - S145
  • [10] Pharmacogenetics of Drug Toxicity
    Daly, A.
    CLINICAL TOXICOLOGY, 2009, 47 (05) : 437 - 437